Tag Archives: Alexion Pharmaceuticals Inc.

Brexit referendum slowing the European Medicines Agency’s operations to a crawl.

The News: The European Medicines Agency (EMA) recently addressed its concerns for ensuring business continuity and staff retention which had become huge challenges caused by the Brexit referendum. The EMA… Read more »

Three healthcare stocks shine while two fizzle to cap the first month of 2019’s investor lottery. Who’s a rational bet and who’s a pure gamble.

The healthcare stock market’s recent success is largely dependent on the fact that, as the global population increases and more people need access to healthcare, companies in the space are prepared… Read more »

Alexion on a roll as Soliris gets label expansion in EU; although flying under the radar, analysts, investors still bullish.

The News: Alexion Pharmaceuticals Inc. (New Haven CT) got another shot in the arm this week with the EU approving its key revenue driver Soliris for an additional indication. EU approval… Read more »

Health sector’s biggest winners & losers as of March 17, 2017

Seres Therapeutics Inc. (Nasdaq: MCRB) led advancing issues, soaring $2.71, or 29% for the week, to $12.04. The small microbiome-therapeutics platform company released its fourth-quarter results earlier Thursday (March 16,… Read more »

Alexion Suddenly Ousts CEO, CFO; what’s really going on?

Alexion Pharmaceuticals Inc. (New Haven CT), maker of one of the world’s most expensive medicines, announced on Monday (December 12, 2106) its CEO and CFO were departing amid an internal… Read more »